Intriguingly, despite their multifunctional properties in cellular contexts, PP2A modulators such as DT-061, have demonstrated pre-clinical promise by selectively targeting cancer cells for death while lacking adverse effects on normal tissues [21–28]. Here, PTPA is linked to cancer.